Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tela Bio Inc (NQ: TELA )

4.470 -0.100 (-2.19%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 127,300
Open 4.480
Bid (Size) 1.780 (2)
Ask (Size) 5.640 (1)
Prev. Close 4.570
Today's Range 4.410 - 4.630
52wk Range 4.235 - 11.17
Shares Outstanding 24,649,595
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
TELA Bio Announces U.S. Commercial Launch of Robotic-Compatible OviTex® IHR – Addressing the Need for a More Natural Repair in Inguinal Hernia Procedures
Targets the more than 665,000 inguinal hernia procedures performed annually in the United States (U.S.) 
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio Welcomes Acclaimed Surgeon as Vice President of Medical Affairs and Surgeon Strategy
Howard N. Langstein, MD, FACS joins innovative MedTech company to leverage his vast experience to help other surgeons optimize clinical outcomes in plastic and reconstructive surgery 
From TELA Bio, Inc.
Via GlobeNewswire

Performance

YTD
-32.48%
-32.48%
1 Month
-17.83%
-17.83%
3 Month
-37.92%
-37.92%
6 Month
-21.02%
-21.02%
1 Year
-52.75%
-52.75%

More News

Read More
Recap: TELA Bio Q4 Earnings
Via Benzinga
Preview: TELA Bio's Earnings
Via Benzinga
Recap: TELA Bio Q3 Earnings
Via Benzinga
TELA Stock Earnings: TELA Bio Misses EPS, Beats Revenue for Q4 2023
Via InvestorPlace
TELA Bio Announces U.S. Commercial Launch of LIQUIFIX™ – the Only FDA-Approved Liquid Adhesive for Internal Use in Hernia Surgery
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio Announces Sale of Distribution Rights for Wound Care Product to MIMEDX
From TELA Bio, Inc.
Via GlobeNewswire
Earnings Scheduled For March 21, 2024
Via Benzinga
TELA Bio to Announce Fourth Quarter and Full Year 2023 Financial Results
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio to Take Part in Connecting the Dots
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio to Participate in Piper Sandler’s 35th Annual Healthcare Conference
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From TELA Bio, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
TELA Bio Reports Third Quarter 2023 Financial Results
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio to Announce Third Quarter 2023 Financial Results
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio to Participate in the Gilmartin Group Emerging Growth Company Showcase
From TELA Bio, Inc.
Via GlobeNewswire
Earnings Scheduled For November 9, 2023
Via Benzinga
TELA Bio Announces U.S. Commercial Launch of OviTex® PRS Long-Term Resorbable for Plastic and Reconstructive Surgery
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio Reports Second Quarter 2023 Financial Results
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio to Announce Second Quarter 2023 Financial Results and Confirms Participation in the Canaccord Genuity 43rd Annual Growth Conference
From TELA Bio, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.